Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2026 10:30 ET | Source: IBA SA

L'IBA lance myQA MatriXX AiR et fait évoluer l'assurance qualité spécifique des patients en thérapie par particules

La première gamme de chambres d'ionisation sans fil pour la thérapie par particules, PSQA, fournissant une vérification rapide et fiable des traitements par protons et ions carbone, et adaptée aux...
March 21, 2026 10:30 ET | Source: IBA SA

IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy

The first wireless ionization chamber array for particle therapy PSQA delivers fast, reliable verification for proton and carbon ion treatments, supporting emerging techniques such as FLASH and ARC...
January 22, 2026 06:46 ET | Source: Research and Markets

Avionics Radiation Dosimetry Research Report 2026: $2+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Avionics Radiation Dosimetry Market Report 2026" has been added to ResearchAndMarkets.com's offering. The avionics radiation dosimetry market is...
November 03, 2025 01:00 ET | Source: IBA SA

IBA intègre l’assurance qualité de l’intelligence artificielle dans ses solutions de dosimétrie grâce à l'acquisition de PhantomX GmbH

Renforcement du portefeuille de Dosimetry avec l'assurance qualité en imagerie médicale et la validation par IA Louvain-la-Neuve, Belgique, le 3 novembre 2025 – IBA (Ion Beam Applications S.A.,...
November 03, 2025 01:00 ET | Source: IBA SA

IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH

Dosimetry portfolio strengthened with Medical Imaging QA and AI validation Louvain-la-Neuve, Belgium, 03 November 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle...
October 08, 2025 06:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress

Study showed targeted tumor uptake with low healthy organ exposure in broad cohort of 207 patientsSupports therapeutic potential of ITM’s proprietary targeted radiotherapeutic agentAbstract receives...
September 08, 2025 11:05 ET | Source: Research and Markets

Brachytherapy Market Trends and Industry Outlook 2025-2030 - AI-Driven Dosimetric Modeling Offers Adaptive Treatment Plans, Projecting Optimal Outcomes Based on Historical Data

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "Brachytherapy Market Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. The Brachytherapy Market is set for significant...
September 04, 2025 07:42 ET | Source: Research and Markets

Brachytherapy Devices Market Growth Opportunities and Competitive Intelligence (2025-2030) Featuring Varian Medical Systems, Elekta, Ion Beam Applications, C. R. Bard, and Eckert & Ziegler Among Others

Dublin, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The "Brachytherapy Devices Market by Product Type (High Dose Rate, Low Dose Rate, Pulsed Dose Rate), Application (Breast Cancer, Cervical Cancer, Ocular...
March 25, 2024 08:02 ET | Source: TeleDaas PLLC

TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters

TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters
November 26, 2023 08:00 ET | Source: TeleDaas PLLC

TeleDaaS™ Launches as Premier Provider of Dosimetry as a Service for Clinical Research Organizations

TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughs.